Pilot study to explore potential benefits of acetazolamide for heart failure patients

Acetazolamide as a chloride-sparing Diuretic in patients Admitted with Heart Failure: a pilot study (ADA-HF), is funded by our BHF CRC Research Development Fund and was successfully added to the NIHR CRN Portfolio.  

This project, led by Dr Joe Cuthbert from Hull York Medical School, aims to investigate the effectiveness of acetazolamide (ACZ) in conjunction with standard diuretic treatment for heart failure (HF). 

Why is this research important? 

Diuretics are commonly used to remove excess fluid in HF patients. However, these medications can also lead to low chloride levels in the blood (hypochloraemia), which has been linked to poorer outcomes. ACZ may offer a solution by acting as a “chloride-sparing diuretic”, potentially improving fluid removal while maintaining chloride levels. 

What will the pilot study involve? 

This pilot study will recruit a minimum of 40 patients admitted to Hull University Teaching Hospitals NHS Trust with HF requiring intravenous furosemide treatment. Participants will be randomly assigned to receive either furosemide alone (standard care) or furosemide combined with oral ACZ. 

The study will assess the impact of ACZ on: 

  • The amount of fluid removed. 
  • Blood chloride levels. 
  • Safety and tolerability of ACZ treatment. 

The results of this pilot study will be crucial in informing the design of a larger, multi-centre trial. This larger trial will definitively determine whether ACZ can improve outcomes for HF patients by preventing or correcting hypochloraemia. 

We are so pleased that the BHF CRC has been able to contribute to this area of work, putting the building blocks in place to potentially develop a larger trial that will significantly benefit patients with heart failure.  

Stay tuned for further updates!